• Komal Dadarao Korde
• Rohini Dattu Kamble

Kristen Rat Sarcoma Virus [KRAS] belongs to family of guanine nucleotide binding proteins. KRAS consist of mutation as G12D, G12V, G13D and Q61H which originates in biliary tract, small intestine, colorectal, lung and pancreatic cancer. KRAS G12D converts inactive GDP to active GTP by GEF which is responsible and tumor formation for this reason it becomes the most targeted site. Targeting the KRAS G12D mutation previously remained a challenge due to lack of druggable pockets on the surface of RAS. Recently, the first selective noncovalent inhibitor MRTX1133 of KRAS G12D was depicted to show activity in preclinical trial and currently it in under phase 1or 2 studied under Mirati Therapeutics Co. Ltd. Various KRAS G12D inhibitors were discovered as HRAS-4642, BI-1701963, BT-1823911, BI-2852, TH-2801, TH-2816 which are under clinical trials. In this, review we summarize the KRAS G12D mutant importance in solid tumors, prior attempts at inhibiting mutant KRAS, and the current promising targets agents being investigated in clinical trials.

KRAS, HRAS, NRAS, oncogene, anticancer, KRAS G12D Inhibitors.

"A REVIEW OF KRAS G12D INHIBITORS: FROM DISCOVERY TO CLINICAL TRIALS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 2, page no.b342-b352, February-2024, Available :http://www.jetir.org/papers/JETIR2402136.pdf

"A REVIEW OF KRAS G12D INHIBITORS: FROM DISCOVERY TO CLINICAL TRIALS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 2, page no. ppb342-b352, February-2024, Available at : http://www.jetir.org/papers/JETIR2402136.pdf